Endocrine Gland Neoplasms: Clinical Trials

8,889 trials for Endocrine Gland Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3874 completed, 1367 recruiting, 1367 unknown, 919 terminated. 2892 Phase 2, 2183 Phase 1, 1727 Not applicable, 620 Phase 3, 151 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 22892Completed 1313, Terminated 421, Recruiting 365, Unknown 335, Active not recruiting 212, Not yet recruiting 115, Withdrawn 115, Suspended 13, Enrolling by invitation 3
Phase 12183Completed 998, Terminated 350, Recruiting 327, Unknown 167, Active not recruiting 162, Withdrawn 100, Not yet recruiting 58, Suspended 20, Enrolling by invitation 1
Not applicable1727Completed 718, Unknown 347, Recruiting 300, Terminated 104, Not yet recruiting 94, Active not recruiting 84, Withdrawn 59, Enrolling by invitation 15, Suspended 6
Phase 3620Completed 268, Recruiting 102, Unknown 91, Terminated 66, Active not recruiting 51, Not yet recruiting 25, Withdrawn 14, Suspended 3
Early Phase 1151Completed 44, Unknown 25, Recruiting 22, Terminated 20, Not yet recruiting 15, Withdrawn 12, Active not recruiting 11, Enrolling by invitation 1, Suspended 1
Phase 4140Completed 66, Unknown 31, Recruiting 13, Terminated 11, Not yet recruiting 9, Active not recruiting 5, Withdrawn 4, Enrolling by invitation 1

Follow Endocrine Gland Neoplasms: new trials by email Literature Review of Endocrine Gland Neoplasms trials Research Report on Endocrine Gland Neoplasms

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC
certepetide, nab-paclitaxel, gemcitabine - Pancreas Cancer, Pancreatic Carcinoma
Phase 1 / Phase 2WithdrawnLisata Therapeutics, Inc.2030-01-012025-06-06
Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors
Exercise and dietary recommendations - Ovarian Cancer
Not applicableNot yet recruitingOncare Madrid322028-05-012026-10-08
Mapping Patient Decision-making in Thyroid Cancer
Decision navigation tool - Thyroid Cancer
Not applicableNot yet recruitingUniversity of California, Los Angeles502028-04-012026-07-24
Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation for the Treatment of Pancreatic Neoplasms
Clinical Intervention or Procedure, Electronic Health Record Review, Endoscopic Ultrasound-Guided Fine-Needle Aspiration of the Pancreas - Pancreatic Neoplasm, Pancreatic Neuroendocrine Tumor
Not applicableEnrolling by invitationOhio State University Comprehensive Cancer Center122027-10-012026-10-13
Pre-Clinic Visit Online Education for Thyroid Cancer
THRIVE, ACS "After a Thyroid Cancer Diagnosis" Flyer - Thyroid Cancer
Not applicableNot yet recruitingCedars-Sinai Medical Center602027-08-012026-09-01
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
Rintatolimod - Pancreatic Cancer
Phase 2SuspendedAIM ImmunoTech Inc.902027-08-012026-08-19
Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation
DN022150+AG( Stage I ), DN022150+AG(Stage II), placebo+AG(Stage II) - Pancreatic Cancer, Pancreatic Carcinoma
Phase 2 / Phase 3Not yet recruitingJiangxi Kvvit Pharmaceutical Co., Ltd.4652027-06-062026-06-18
Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma
Biospecimen Collection, Diagnostic Imaging Testing, Echocardiography Test - Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)312027-06-012026-10-22
Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery
Indocyanine Green, Near-Infrared Fluorescence Imaging System - Gynecologic Cancers, Ovarian Cancer
Phase 4Not yet recruitingIstanbul University502027-06-012026-11-18
Daraxonrasib in Resectable PDAC
Daraxonrasib, Surgical Resection, Adjuvant Chemotherapy - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Phase 1Not yet recruitingDana-Farber Cancer Institute302027-04-132026-10-27
PITCH - Impacting Hereditary Cancer Testing
Genetic testing education video - Ovarian Cancer, Genetic Testing
Not applicableNot yet recruitingRachel Miller2002027-04-012026-09-10
A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer
EF-009 - Pancreatic Cancer
Phase 1 / Phase 2Not yet recruitingEverfront Biotech Co., Ltd.302027-04-012026-09-11
A Prospective Study of Concurrent Hyperthermia, Chemotherapy and Radiotherapy in Borderline and Locally Advanced Pancreatic Cancer (PANHEAT)
Hyperthermia plus neoadjuvant chemotherapy/radiotherapy Arm Description: Hyperthermia plus neoadjuvant chemotherapy (mFOLFIRINOX/nab Paclitaxel) followed by a) surgically resectable: Hyp - Borderline and Locally Advanced Pancreatic Cancer
Not applicableNot yet recruitingFernando Pessoa Canarias University602027-03-312026-09-24
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
R-DXd, Bevacizumab - Fallopian Tube Cancer, Primary Peritoneal Cancer
Phase 3Not yet recruitingDaiichi Sankyo6002027-03-312026-11-13
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
Ivonescimab - Adrenocortical Carcinoma, Pheochromocytoma
Phase 2Not yet recruitingM.D. Anderson Cancer Center202027-02-072026-09-18
Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer
losartan, Paclitaxel - Platinum Resistant Ovarian Cancer
Phase 2Not yet recruitingMassachusetts General Hospital272027-02-012026-09-22
A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer
Navlimetostat, mFOLFIRINOX Treatment Regimen - Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 1 / Phase 2Not yet recruitingDaniel Nussbaum, M.D.182027-01-152026-11-02
Helping Young People With Testicular Cancer Using Virtual and Extended Reality
Digital tool using extended reality - Testicular Cancer, Testis Cancer
Not applicableNot yet recruitingGustave Roussy, Cancer Campus, Grand Paris2452027-01-042026-05-06
Predicting Pancreatic Fistula After Pancreatic Surgery Using Preoperative Immunity
blood sampling - Pancreatic Cancer
Not yet recruitingInstitut Paoli-Calmettes3102027-01-042026-09-18
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
Diagnostic DNA Methylation Signature - Thyroid Gland Nodule
RecruitingCity of Hope Medical Center222027-01-012026-06-02

Showing 20 of 8889. Sign in to see all of them.

Narrower conditions

Pancreatic Neoplasms (3688)  ·  Ovarian Neoplasms (3276)  ·  Breast Neoplasms (883)  ·  Carcinoma, Ovarian Epithelial (787)  ·  Fallopian Tube Neoplasms (783)  ·  Thyroid Neoplasms (722)  ·  Neoplasms (679)  ·  Colorectal Neoplasms (626)  ·  Stomach Neoplasms (541)  ·  Carcinoma, Non-Small-Cell Lung (538)  ·  Endometrial Neoplasms (474)  ·  Lung Neoplasms (445)  ·  Uterine Cervical Neoplasms (395)  ·  Neoplasm Metastasis (391)  ·  Prostatic Neoplasms (351)

Broader conditions

Endocrine System Diseases (8864)  ·  Neoplasms by Site (8854)  ·  Neoplasms (8210)  ·  Digestive System Diseases (4431)  ·  Digestive System Neoplasms (4390)  ·  Urogenital Diseases (4112)  ·  Urogenital Neoplasms (4034)  ·  Genital Diseases (4006)  ·  Female Urogenital Diseases (3900)  ·  Female Urogenital Diseases and Pregnancy Complications (3900)  ·  Gonadal Disorders (3868)  ·  Pancreatic Diseases (3842)  ·  Genital Diseases, Female (3734)  ·  Genital Neoplasms, Female (3707)

Interventions

Gemcitabine (814)  ·  Paclitaxel (422)  ·  Carboplatin (404)  ·  Bevacizumab (268)  ·  130-nm albumin-bound paclitaxel (226)  ·  Fluorouracil (215)  ·  Cisplatin (211)  ·  Oxaliplatin (207)  ·  pembrolizumab (199)  ·  Albumin-Bound Paclitaxel (186)  ·  Capecitabine (162)  ·  Cyclophosphamide (157)  ·  Leucovorin (152)  ·  Taxes (147)  ·  Irinotecan (130)

Sponsors

National Cancer Institute (NCI) (347)  ·  M.D. Anderson Cancer Center (176)  ·  Memorial Sloan Kettering Cancer Center (162)  ·  Mayo Clinic (82)  ·  Fudan University (78)  ·  Gynecologic Oncology Group (76)  ·  AstraZeneca (71)  ·  Dana-Farber Cancer Institute (70)  ·  Fondazione Policlinico Universitario Agostino Gemelli IRCCS (61)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (61)  ·  Peking Union Medical College Hospital (60)  ·  Eli Lilly and Company (57)  ·  University Health Network, Toronto (57)  ·  Massachusetts General Hospital (50)  ·  City of Hope Medical Center (49)

Countries

United States (4206)  ·  China (1183)  ·  France (655)  ·  Italy (617)  ·  Canada (567)  ·  United Kingdom (527)  ·  Spain (511)  ·  South Korea (443)  ·  Germany (441)  ·  Belgium (332)  ·  Australia (326)  ·  Netherlands (313)  ·  Denmark (229)  ·  Japan (229)  ·  Taiwan (202)

Top investigators

Lei Li, M.D. (14)  ·  Paul Sabbatini, MD (13)  ·  Saleh K Saleh, MD (13)

Results publications

PMID 37185961, PMID 37407274, PMID 39863139, PMID 35170751, PMID 33337539, PMID 39695768, PMID 40668552, PMID 19238149, PMID 22551107, PMID 30633128, PMID 37598000, PMID 20818904, PMID 21561347, PMID 23433878, PMID 23922302, PMID 24131140, PMID 26961146, PMID 28733257, PMID 29342393, PMID 35537408, PMID 36512649, PMID 37934000, PMID 39019698, PMID 41044356, PMID 15273542, PMID 15855973, PMID 16394300, PMID 21420083, PMID 21941283, PMID 22154461, PMID 23547081, PMID 25968622, PMID 26707054, PMID 28040257, PMID 31401903, PMID 32379297, PMID 35262624, PMID 35397664, PMID 40056080, PMID 40132910, PMID 40341199, PMID 42836590, PMID 12826431, PMID 15908661, PMID 16172198, PMID 16882940, PMID 16966687, PMID 17000396, PMID 17554118, PMID 17949799

NIH funding

U10CA027469 (56), 2023 (54), U10CA180868 (42), 2016 (36), 2025 (36), 2018 (33), P30CA033572 (31), 2015 (29), 2017 (29), P30CA015083 (29), P30CA016672 (25), 2019 (24), 2014 (23), 2008 (21), 2009 (20)